Shares of La Jolla Pharmaceutical Company LJPC, -54.12% fell 30% in premarket trading after it announced president and CEO George Tidmarsh had left the company and that the company plans to "re-evaluate its current operating plan" following mixed-results in two clinical studies. La Jolla said it discontinued one study evaluating its experimental treatment, LJPC-401, for iron overload in some patients with beta thalassemia over a lack of efficacy.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,